Posted by Michael Wonder on 28 Nov 2019
Takhzyro (lanadelumab injection) receives positive recommendation from CADTH's Canadian Drug Expert Committee for the routine prevention of hereditary angioedema attacks
22 November 2019 - The positive recommendation is supported by the recently released findings of the Phase 3 Help Study™ Open-Label Extension in HAE.
Takeda Canada Inc. is pleased to announce that the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee has issued a positive recommendation that Takhzyro (lanadelumab injection) be reimbursed by public drug plans for routine prevention of hereditary angioedema attacks in adolescents and adults (12 years of age and older).
